Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602086 | 0.76 | FGFR3 (0.46) | KDRFGFR3FLT3 | |
| SCHEMBL4552760 | 0.72 | KDR (0.44) | KDRFGFR3FLT3 | |
| SCHEMBL13336965 | 0.71 | NOTUM (0.41) | KDRCSF1R | |
| SCHEMBL3321603 | 0.70 | FLT3 (0.62) | KDRFGFR3FLT3 | |
| SCHEMBL1431511 | 0.70 | KDR (0.45) | KDRFGFR3FLT3 | |
| SCHEMBL5249616 | 0.68 | KDR (0.45) | KDRFGFR3FLT3 | |
| SCHEMBL3189260 | 0.68 | KDR (0.63) | KDRFGFR3FLT3 | |
| SCHEMBL3188804 | 0.68 | KDR (0.45) | KDRFGFR3FLT3 | |
| SCHEMBL11925640 | 0.68 | KDR (0.46) | KDRFGFR3FLT3 | |
| SCHEMBL3320264 | 0.68 | KDR (0.36) | KDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419428-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-8722687-B2 | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy | ASTEX THERAPEUTICS LTD (GB) | 2014-05-13 | — | — | US | disclosed |
| EP-2419428-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | Astex Therapeutics Ltd. (GB) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010119285-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041000-A1 | IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY | FGFR1, FGFR3, FGFR2 | KDR 41/4885FGFR3 2/4885CSF1R 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.